Journal: Frontiers in Oncology
Article Title: A novel prognostic signature based on mitochondrial permeability transition-driven necrosis genes for biochemical recurrence prediction in prostate cancer
doi: 10.3389/fonc.2026.1775602
Figure Lengend Snippet: Validation of FNDC1, S100A8, and TREM2 expression. (A) The mRNA expression levels of FNDC1, S100A8, and TREM2 in TCGA-PRAD cohort. (B) The mRNA expression levels of FNDC1, S100A8 and TREM2 were confirmed by q-PCR between paratumor(PT) and prostate cancer tissue. (C, D) The protein expression levels of FNDC1, S100A8 and TREM2 were confirmed by western blot between paratumor(PT) and prostate cancer tissue(T). (E) Immunohistochemistry micrographs revealing FNDC1, S100A8 and TREM2 expression between paratumor(PT) and prostate cancer tissue(T). **P< 0.01; ***P< 0.001.
Article Snippet: The following were the antibody concentrations for western blotting: rabbit polyclonal anti-FNDC1 antibody (1:1000, catalog no. bs-8460R; Bioss, Beijing, China), rabbit polyclonal anti-TREM2 antibody (1:1000, catalog no. HY- P80920 ; MedChemExpress, Monmouth Junction, NJ, USA), and rabbit polyclonal anti-S100A8 antibody (1:1000, catalog no. AF7929; Beyotime, Shanghai, China), and mouse monoclonal anti-GAPDH (1:2000, 60004-1-Ig, Proteintech, China).
Techniques: Biomarker Discovery, Expressing, Western Blot, Immunohistochemistry